Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of options to purchase up to 188,100 shares of common stock. The stock options have a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

FAQ

What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in May 2025?

Syndax granted stock options to purchase up to 188,100 shares of common stock under its 2023 Inducement Plan.

How many employees received inducement grants from SNDX in May 2025?

Seven new employees received inducement grants from Syndax Pharmaceuticals.

What is the vesting schedule for SNDX's May 2025 inducement stock options?

The options vest over 4 years, with 25% vesting after one year and 1/48th vesting monthly over the next 36 months, subject to continued employment.

When did Syndax Pharmaceuticals (SNDX) grant the inducement awards?

Syndax granted the inducement awards on May 1, 2025.